Urogen Pharma (URGN) Projected to Post Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.4824) per share and revenue of $44.8280 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Urogen Pharma Stock Performance

Urogen Pharma stock traded up $0.07 during trading hours on Tuesday, reaching $23.36. 134,581 shares of the stock were exchanged, compared to its average volume of 770,982. The stock has a market cap of $1.14 billion, a P/E ratio of -7.31 and a beta of 1.58. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00. The firm’s 50 day moving average is $20.32 and its 200 day moving average is $21.39.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after purchasing an additional 24,839 shares during the period. Cetera Investment Advisers purchased a new position in Urogen Pharma during the second quarter valued at approximately $361,000. Finally, JPMorgan Chase & Co. increased its stake in Urogen Pharma by 5.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after buying an additional 19,405 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on URGN. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. D. Boral Capital reissued a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.13.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.